{"id":950569,"date":"2026-04-10T16:07:28","date_gmt":"2026-04-10T20:07:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/"},"modified":"2026-04-10T16:07:28","modified_gmt":"2026-04-10T20:07:28","slug":"allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/","title":{"rendered":"Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SOUTH SAN FRANCISCO, Calif., April  10, 2026  (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the Company will host a conference call and webcast to review the interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial with cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation large B-cell lymphoma (LBCL) on Monday, April 13, 2026.<\/p>\n<p>The live conference call and webcast will take place at 5:30 a.m. PT \/ 8:30 a.m. ET. Please use this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CO53VzO6YhIThxinbJT9Njw-jrlXe2z5Y4ECRjJQOKODhaYghqLkcJ4SYYceagfk3Pucrrg_SMyM_S9E2BjU5sgfp-MA6Q9vlGpG5U3RPE4=\" rel=\"nofollow\" target=\"_blank\">link<\/a> to register. The webcast will be made available on the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q1LQ2OcFoIcES_TvbZFgyhrIpR_fifahYBe-4ItXP_W9LA-ku1WiqE8oE68DCGcMPfuHvidNauk7cYCWwDeMYKSq9-5lcNhW6QwW_rs7dkw=\" rel=\"nofollow\" target=\"_blank\">www.allogene.com<\/a> under the Investors tab in the News and Events section.<\/p>\n<p>\n        <strong>About Allogene Therapeutics<\/strong><br \/>\n        <br \/>Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of \u201coff-the-shelf\u201d CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q1LQ2OcFoIcES_TvbZFgyk-RBLGTMxy5jcx10CMPvwLxJGTu7fcvNGY8LXcrtzaFS4zG34S-SrSlUN-BBehvzvUXzBJSvPMPAPqiJONeWuI=\" rel=\"nofollow\" target=\"_blank\">www.allogene.com<\/a>, and follow Allogene Therapeutics on X and LinkedIn.<\/p>\n<p>\n        <strong>Allogene Media\/Investor Contact:<\/strong><br \/>\n        <br \/>Christine Cassiano<br \/>EVP, Chief Corporate Affairs &amp; Brand Strategy Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xbtFWhpzARlCSAoksZPgZCr7XyuHFkTcKw0H9wxOZQg6zLBmJjSZfYz82h-_80EKeLX2SfxM_d3CFEX2lA62AsZJnO8Ljh1st7UIrC2NmEA9l6z6nCsP8ojcrTw545wH\" rel=\"nofollow\" target=\"_blank\">Christine.Cassiano@allogene.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NzMzNSM3NTI4NjU0IzIxMjQyNDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzE4MjM2ZGItZGIzOS00OTdmLWJmOGQtODdmMzBiNDRiNmUwLTExMzU4MTgtMjAyNi0wNC0xMC1lbg==\/tiny\/Allogene-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the Company will host a conference call and webcast to review the interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial with cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation large B-cell lymphoma (LBCL) on Monday, April 13, 2026. The live conference call and webcast will take place at 5:30 a.m. PT \/ 8:30 a.m. ET. Please use this link to register. The webcast will be made available on the Company&#8217;s website at www.allogene.com under the Investors tab in the News and Events &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-950569","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the Company will host a conference call and webcast to review the interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial with cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation large B-cell lymphoma (LBCL) on Monday, April 13, 2026. The live conference call and webcast will take place at 5:30 a.m. PT \/ 8:30 a.m. ET. Please use this link to register. The webcast will be made available on the Company&#8217;s website at www.allogene.com under the Investors tab in the News and Events &hellip; Continue reading &quot;Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-10T20:07:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NzMzNSM3NTI4NjU0IzIxMjQyNDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026\",\"datePublished\":\"2026-04-10T20:07:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\\\/\"},\"wordCount\":250,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NzMzNSM3NTI4NjU0IzIxMjQyNDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\\\/\",\"name\":\"Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NzMzNSM3NTI4NjU0IzIxMjQyNDc=\",\"datePublished\":\"2026-04-10T20:07:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NzMzNSM3NTI4NjU0IzIxMjQyNDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NzMzNSM3NTI4NjU0IzIxMjQyNDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/","og_locale":"en_US","og_type":"article","og_title":"Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the Company will host a conference call and webcast to review the interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial with cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation large B-cell lymphoma (LBCL) on Monday, April 13, 2026. The live conference call and webcast will take place at 5:30 a.m. PT \/ 8:30 a.m. ET. Please use this link to register. The webcast will be made available on the Company&#8217;s website at www.allogene.com under the Investors tab in the News and Events &hellip; Continue reading \"Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-10T20:07:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NzMzNSM3NTI4NjU0IzIxMjQyNDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026","datePublished":"2026-04-10T20:07:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/"},"wordCount":250,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NzMzNSM3NTI4NjU0IzIxMjQyNDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/","name":"Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NzMzNSM3NTI4NjU0IzIxMjQyNDc=","datePublished":"2026-04-10T20:07:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NzMzNSM3NTI4NjU0IzIxMjQyNDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NzMzNSM3NTI4NjU0IzIxMjQyNDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=950569"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950569\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=950569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=950569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=950569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}